Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04656249 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer(LENABC) | completed | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04642664 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer(ACABC) | completed | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 |
| Jun 3, 2021 |
| clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT04739046 | An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | unknown | Phase 2 | 12 | Seoul National University Bundang HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer(BILHER) | completed | Phase 2 | 4 | Changhoon YooOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01247337 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | completed | Phase 2 | 56 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT01222689 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02428855 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04216758 | Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | unknown | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | terminated | Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | completed | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02456714 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma(4CC) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02635971 | Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 168 | Fudan UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00779454 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | completed | Phase 2 | 72 | Vejle HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2021source: clinicaltrials